An Nrf2 inhibitor (ML385) used to further confirm the protective effect of Bcl3 deficiency was based on activation of the Nrf2 pathway (Figure 8A).35 Here, BCL3 is linked to hyperinsulinemic hypoglycemia, familial, 4.